NO981522L - Aminosyrederivater, deres fremstilling og anvendelse som endotelinantagonister - Google Patents
Aminosyrederivater, deres fremstilling og anvendelse som endotelinantagonisterInfo
- Publication number
- NO981522L NO981522L NO981522A NO981522A NO981522L NO 981522 L NO981522 L NO 981522L NO 981522 A NO981522 A NO 981522A NO 981522 A NO981522 A NO 981522A NO 981522 L NO981522 L NO 981522L
- Authority
- NO
- Norway
- Prior art keywords
- preparation
- amino acid
- acid derivatives
- endothelin antagonists
- endothelin
- Prior art date
Links
- 102000002045 Endothelin Human genes 0.000 title 1
- 108050009340 Endothelin Proteins 0.000 title 1
- 150000003862 amino acid derivatives Chemical class 0.000 title 1
- 239000005557 antagonist Substances 0.000 title 1
- ZUBDGKVDJUIMQQ-UBFCDGJISA-N endothelin-1 Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)NC(=O)[C@H]1NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@@H](CC=2C=CC(O)=CC=2)NC(=O)[C@H](C(C)C)NC(=O)[C@H]2CSSC[C@@H](C(N[C@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N2)=O)NC(=O)[C@@H](CO)NC(=O)[C@H](N)CSSC1)C1=CNC=N1 ZUBDGKVDJUIMQQ-UBFCDGJISA-N 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/36—Antigestagens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/52—Two oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/58—Two sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
- C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
- C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D251/26—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hetero atoms directly attached to ring carbon atoms
- C07D251/40—Nitrogen atoms
- C07D251/42—One nitrogen atom
- C07D251/46—One nitrogen atom with oxygen or sulfur atoms attached to the two other ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Peptides Or Proteins (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19536891A DE19536891A1 (de) | 1995-10-04 | 1995-10-04 | Neue Aminosäurederivate, ihre Herstellung und Verwendung |
| PCT/EP1996/004205 WO1997012878A1 (de) | 1995-10-04 | 1996-09-26 | Aminosäurederivate, ihre herstellung und verwendung als endothelinantagonisten |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO981522D0 NO981522D0 (no) | 1998-04-03 |
| NO981522L true NO981522L (no) | 1998-04-03 |
| NO311025B1 NO311025B1 (no) | 2001-10-01 |
Family
ID=7773950
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO19981522A NO311025B1 (no) | 1995-10-04 | 1998-04-03 | Aminosyrederivater, legemiddel inneholdende dem og anvendelse som endotelinantagonister |
Country Status (24)
| Country | Link |
|---|---|
| US (1) | US6440975B1 (no) |
| EP (1) | EP0874829A1 (no) |
| JP (1) | JP2000500738A (no) |
| KR (1) | KR19990063998A (no) |
| CN (1) | CN1202890A (no) |
| AU (1) | AU713763B2 (no) |
| BG (1) | BG63389B1 (no) |
| BR (1) | BR9610821A (no) |
| CA (1) | CA2231500A1 (no) |
| CO (1) | CO4770961A1 (no) |
| CZ (1) | CZ104598A3 (no) |
| DE (1) | DE19536891A1 (no) |
| HR (1) | HRP960437A2 (no) |
| HU (1) | HUP9900085A3 (no) |
| IL (1) | IL123611A (no) |
| MX (1) | MX9801987A (no) |
| MY (1) | MY115211A (no) |
| NO (1) | NO311025B1 (no) |
| NZ (1) | NZ319595A (no) |
| PL (1) | PL326081A1 (no) |
| SK (1) | SK43098A3 (no) |
| TR (1) | TR199800623T2 (no) |
| WO (1) | WO1997012878A1 (no) |
| ZA (1) | ZA968304B (no) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19636046A1 (de) | 1996-09-05 | 1998-03-12 | Basf Ag | Neue Carbonsäurederivate, ihre Herstellung und Verwendung als gemischte ET¶A¶/ET¶B¶-Rezeptorantagonisten |
| US6143743A (en) | 1997-07-03 | 2000-11-07 | Dupont Pharmaceuticals Company | Imidazopyrimidines and imidazopyridines for the treatment of neurological disorders |
| US6124463A (en) * | 1998-07-02 | 2000-09-26 | Dupont Pharmaceuticals | Benzimidazoles as corticotropin release factor antagonists |
| US6365589B1 (en) | 1998-07-02 | 2002-04-02 | Bristol-Myers Squibb Pharma Company | Imidazo-pyridines, -pyridazines, and -triazines as corticotropin releasing factor antagonists |
| CA2359115C (en) * | 1999-01-22 | 2011-06-21 | Elan Pharmaceuticals, Inc. | Acyl derivatives which treat vla-4 related disorders |
| JP2004525069A (ja) | 2000-06-15 | 2004-08-19 | ファルマシア・コーポレーション | インテグリン受容体アンタゴニストとしてのシクロアルキルアルカン酸 |
| US6531494B1 (en) | 2001-08-29 | 2003-03-11 | Pharmacia Corporation | Gem-substituted αvβ3 antagonists |
| RU2003120061A (ru) * | 2000-12-07 | 2004-11-27 | Си Ви Терапьютикс, Инк. (Us) | Замещенные 1,3,5-триазины и пиримидины в качестве повышающих авса-1 соединений против заболевания коронарной артерии или атеросклероза |
| TWI281470B (en) | 2002-05-24 | 2007-05-21 | Elan Pharm Inc | Heterocyclic compounds which inhibit leukocyte adhesion mediated by alpha4 integrins |
| TW200307671A (en) | 2002-05-24 | 2003-12-16 | Elan Pharm Inc | Heteroaryl compounds which inhibit leukocyte adhesion mediated by α 4 integrins |
| EP1713793A4 (en) * | 2004-02-04 | 2009-09-02 | Smithkline Beecham Corp | PYRIMIDINONE COMPOUNDS SUITED AS KINASEINHIBITORS |
| EP1940827B1 (en) | 2005-09-29 | 2011-03-16 | Elan Pharmaceuticals Inc. | Carbamate compounds which inhibit leukocyte adhesion mediated by vla-4 |
| ZA200803280B (en) | 2005-09-29 | 2009-11-25 | Elan Pharm Inc | Pyrimidinyl amide compounds which inhibit leukocyte adhesion mediated by VLA-4 |
| CN101389611B (zh) | 2006-02-27 | 2012-07-18 | 伊兰制药公司 | 抑制由vla-4所介导的白血球粘附的嘧啶磺酰胺化合物 |
| CN1908183B (zh) * | 2006-08-16 | 2010-09-29 | 上海奥利实业有限公司 | 具内皮素拮抗作用的天然蛋白的酶解混合肽 |
| US8497276B2 (en) | 2009-03-31 | 2013-07-30 | Arqule, Inc. | Substituted indolo-piperidine compounds |
| SG175355A1 (en) | 2009-04-27 | 2011-12-29 | Elan Pharm Inc | Pyridinone antagonists of alpha-4 integrins |
| PE20170682A1 (es) | 2014-08-04 | 2017-06-15 | Nuevolution As | Derivados de pirimidina sustituidos con heterociclilo opcionalmente condensados utiles para el tratamiento de enfermedades inflamatorias, metabolicas, oncologicas y autoinmunitarias |
| US11447479B2 (en) | 2019-12-20 | 2022-09-20 | Nuevolution A/S | Compounds active towards nuclear receptors |
| JP2023519605A (ja) | 2020-03-31 | 2023-05-11 | ヌエヴォリューション・アクティーゼルスカブ | 核内受容体に対して活性な化合物 |
| WO2021198955A1 (en) | 2020-03-31 | 2021-10-07 | Nuevolution A/S | Compounds active towards nuclear receptors |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4092150A (en) * | 1976-08-27 | 1978-05-30 | Fmc Corporation | Herbicidal 5-pyrimidinecarbonitriles |
| EP0347811B1 (en) * | 1988-06-20 | 1994-03-30 | Kumiai Chemical Industry Co., Ltd. | Alkanoic acid derivatives and herbicidal compositions |
| CA2053603A1 (en) * | 1990-10-19 | 1992-04-20 | Katsumasa Harada | 3-alkoxyalkanoic acid derivative, process for preparing the same and herbicide using the same |
| DE4105518A1 (de) | 1991-02-22 | 1992-08-27 | Basf Ag | Sulfonylharnstoffderivate, verfahren zu ihrer herstellung und ihre verwendung |
| DE69226813T2 (de) | 1991-06-07 | 1999-02-18 | Ube Industries, Ltd., Ube, Yamaguchi | Pyrimidin- oder Triazin-Derivate, Verfahren zu ihrer Herstellung und diese enthaltende Herbizide |
| DE4411225A1 (de) * | 1994-03-31 | 1995-10-05 | Basf Ag | Verwendung von Carbonsäurederivaten als Arzneimittel |
| DE19533023B4 (de) * | 1994-10-14 | 2007-05-16 | Basf Ag | Neue Carbonsäurederivate, ihre Herstellung und Verwendung |
| US5958934A (en) * | 1996-05-23 | 1999-09-28 | Syntex (U.S.A.) Inc. | Aryl pyrimidine derivatives and uses thereof |
-
1995
- 1995-10-04 DE DE19536891A patent/DE19536891A1/de not_active Withdrawn
-
1996
- 1996-09-26 JP JP9513946A patent/JP2000500738A/ja not_active Abandoned
- 1996-09-26 EP EP96933398A patent/EP0874829A1/de not_active Withdrawn
- 1996-09-26 HR HR19536891.6A patent/HRP960437A2/hr not_active Application Discontinuation
- 1996-09-26 CZ CZ981045A patent/CZ104598A3/cs unknown
- 1996-09-26 US US09/051,020 patent/US6440975B1/en not_active Expired - Lifetime
- 1996-09-26 WO PCT/EP1996/004205 patent/WO1997012878A1/de not_active Application Discontinuation
- 1996-09-26 CA CA002231500A patent/CA2231500A1/en not_active Abandoned
- 1996-09-26 SK SK430-98A patent/SK43098A3/sk unknown
- 1996-09-26 AU AU72147/96A patent/AU713763B2/en not_active Ceased
- 1996-09-26 TR TR1998/00623T patent/TR199800623T2/xx unknown
- 1996-09-26 IL IL12361196A patent/IL123611A/xx not_active IP Right Cessation
- 1996-09-26 PL PL96326081A patent/PL326081A1/xx unknown
- 1996-09-26 HU HU9900085A patent/HUP9900085A3/hu unknown
- 1996-09-26 KR KR1019980702475A patent/KR19990063998A/ko not_active Application Discontinuation
- 1996-09-26 CN CN96198556A patent/CN1202890A/zh active Pending
- 1996-09-26 BR BR9610821A patent/BR9610821A/pt not_active Application Discontinuation
- 1996-09-26 NZ NZ319595A patent/NZ319595A/en unknown
- 1996-09-27 MY MYPI96004014A patent/MY115211A/en unknown
- 1996-10-03 ZA ZA9608304A patent/ZA968304B/xx unknown
- 1996-10-03 CO CO96052652A patent/CO4770961A1/es unknown
-
1998
- 1998-03-13 MX MX9801987A patent/MX9801987A/es not_active IP Right Cessation
- 1998-04-01 BG BG102362A patent/BG63389B1/bg unknown
- 1998-04-03 NO NO19981522A patent/NO311025B1/no not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| PL326081A1 (en) | 1998-08-17 |
| ZA968304B (en) | 1998-04-03 |
| MY115211A (en) | 2003-04-30 |
| BG102362A (en) | 1999-08-31 |
| HUP9900085A2 (hu) | 1999-04-28 |
| EP0874829A1 (de) | 1998-11-04 |
| CA2231500A1 (en) | 1997-04-10 |
| TR199800623T2 (xx) | 1998-07-21 |
| AU713763B2 (en) | 1999-12-09 |
| BR9610821A (pt) | 1999-07-13 |
| HUP9900085A3 (en) | 2001-11-28 |
| HRP960437A2 (en) | 1998-04-30 |
| BG63389B1 (bg) | 2001-12-29 |
| IL123611A0 (en) | 1998-10-30 |
| WO1997012878A1 (de) | 1997-04-10 |
| NO981522D0 (no) | 1998-04-03 |
| DE19536891A1 (de) | 1997-04-10 |
| US6440975B1 (en) | 2002-08-27 |
| JP2000500738A (ja) | 2000-01-25 |
| CZ104598A3 (cs) | 1998-09-16 |
| NZ319595A (en) | 2001-03-30 |
| NO311025B1 (no) | 2001-10-01 |
| MX9801987A (es) | 1998-08-30 |
| IL123611A (en) | 2001-08-26 |
| CN1202890A (zh) | 1998-12-23 |
| SK43098A3 (en) | 1998-11-04 |
| AU7214796A (en) | 1997-04-28 |
| CO4770961A1 (es) | 1999-04-30 |
| KR19990063998A (ko) | 1999-07-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO981522L (no) | Aminosyrederivater, deres fremstilling og anvendelse som endotelinantagonister | |
| DK1538160T3 (da) | Substituerede isochinolin-3-carboxylsyreamider, deres fremstilling og deres anvendelse som lægemiddel | |
| DK0832082T3 (da) | N-heteroaryl-pyridinsulfonamidderivater og deres anvendelse som endotelinantagonister | |
| NO991815D0 (no) | Oksadiazoler, fremgangsmÕter for deres fremstilling og deres anvendelse som medikamenter | |
| DK0832104T3 (da) | Dolastatinderivater, deres fremstilling og anvendelse | |
| NO20006029D0 (no) | Pyrazolinderivater, deres fremstilling og anvendelse som legemidler | |
| DK1006110T3 (da) | Derivater af acylpiperazinylpyrimidiner, fremstilling deraf og anvendelse som lægemidler | |
| DK1019358T3 (da) | 3,3-diarylpropylaminer, deres anvendelse og fremstilling | |
| NO975513L (no) | 3-hydroksypyridin-2-karboksylsyreamidester, fremstilling og anvendelse som legemiddel | |
| NO20005146L (no) | Tienylazolylalkoksyetanaminer, deres fremstilling og deres anvendelse som medikamenter | |
| NO991079L (no) | Azinyloksy- og fenoksy-diaryl-karboksylsyre-derivater, deres fremstilling og deres anvendelse som blandede ETA/ETB-endotelin-reseptor-antagonister | |
| NO996115D0 (no) | Azetidinylpropylpiperidin-derivater, intermediater og anvendelse som tachykinin-antagonister | |
| DK0931081T3 (da) | Pyridazino-[4,5-B]-quinolin-5-oxid-derivater, deres fremstilling og deres anvendelse som glycinantagonister | |
| DK0839146T3 (da) | Piperazinderivater og deres anvendelse som 5-HT1A-antagonister | |
| NO995513L (no) | N-triazolyl-2-indolkarboksamider og deres anvendelse som CCK- | |
| NO951418D0 (no) | Peptidderivater, deres fremstilling og anvendelse som terapeutika | |
| NO20001934D0 (no) | 3-Substituerte tetrahydropyridopyrimidinon-derivater, deres fremstilling og anvendelse | |
| NO992976L (no) | Heterocykliske karboksylsyre-derivater, fremstilling og anvendelse derav som endothelinreseptor-antagonister | |
| DK619989D0 (da) | Dipeptidderivater, deres fremstilling og anvendelse som laegemidler | |
| NO20000066D0 (no) | 6-pyrrolidin-2-ylpyrindin-derivater, deres fremstilling og deres farmasoeytiske anvendelse | |
| NO981002L (no) | Karboksylsyrederivater, deres fremstilling og anvendelse | |
| NO996244D0 (no) | Pyrrolidinkarboksylsyrederivater som endotelinantagonister | |
| NO20004075D0 (no) | Substituerte pyrimidin-2-yloksy-karboksylsyrederivater, fremstilling av disse og deres anvendelse som endotelin- antagonister | |
| DK1235809T3 (da) | Substituerede 1,2,3,4,5,6-hexahydro-2,6-methano-3-benzazociner og deres anvendelse som lægemidler | |
| DK1072266T3 (da) | Thienylazolylalkoxyethanaminer, deres fremstilling og deres anvendelse som lægemidler |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM1K | Lapsed by not paying the annual fees |
Free format text: LAPSED IN MARCH 2003 |